keyword
MENU ▼
Read by QxMD icon Read
search

R-chop

keyword
https://www.readbyqxmd.com/read/28719025/frequency-risk-factors-and-outcomes-of-central-nervous-system-relapse-in-lymphoma-patients-treated-with-dose-adjusted-epoch-plus-rituximab
#1
M K Malecek, A M Petrich, S Rozell, B Chu, S Trifilio, N Galanina, M Maurer, U Farooq, B Link, G S Nowakowski, C Nabhan, A O Ayed
Background Central nervous system (CNS) relapse in non-Hodgkin lymphoma (NHL) is a rare but serious complication that carries a poor prognosis. The use of infusional etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) for frontline treatment of diffuse large B cell lymphoma (DLBCL) is increasing, though little is known about incidence of and risk factors for CNS relapse with this regimen Patients and methods We completed a chart review of patients with NHL who received EPOCH-R as front line therapy...
July 18, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28714143/efficacy-and-safety-of-new-direct-antiviral-agents-in-hcv-infected-patients-with-diffuse-large-b-cell-non-hodgkin-lymphoma
#2
Marcello Persico, Andrea Aglitti, Rosa Caruso, Amalia De Renzo, Carmine Selleri, Catello Califano, Ludovico Abenavoli, Alessandro Federico, Mario Masarone
INTRODUCTION: The association of HCV with Non-Hodgkin Lymphoma (NHL) has been demonstrated all over the world. The new interferon-free, direct antiviral agents (DAA), showed high efficacy and safety, and preliminary data seem to confirm their activity on low-grade NHL. The question arises as whether or not -and how- to treat the HCV positive patients suffering from diffuse large B cell lymphomas(DLBCL). Aim of this observational study was to evaluate whether the DAAs antiviral treatment of DLBCL/HCV-infected patients in concomitance with chemotherapy is a safe and effective option...
July 17, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28712322/is-now-the-time-for-molecular-driven-therapy-for-diffuse-large-b-cell-lymphoma
#3
Alice Di Rocco, Federico De Angelis, Michela Ansuinelli, Robin Foà, Maurizio Martelli
Recent genetic and molecular discoveries regarding alterations in diffuse large B-cell lymphoma (DLBCL) deeply changed the approach to this lymphoproliferative disorder. Novel additional predictors of outcomes and new therapeutic strategies are being introduced to improve outcomes. Areas covered: This review aims to analyse the recent molecular discoveries in DLBCL, the rationale of novel molecular driven treatments and their impact on DLBCL prognosis, especially in ABC-DLBCL and High Grade B Cell Lymphoma...
July 17, 2017: Expert Review of Hematology
https://www.readbyqxmd.com/read/28711572/emerging-strategies-in-treating-double-hit-lymphomas
#4
REVIEW
Chadi Nabhan, Anthony R Mato
Double hit lymphomas (DHLs) are a new category in the World Health Organization newest classification for lymphoid malignancies. DHL encompasses various histologies of lymphomas where the MYC oncogene and either BCL2 or BCL6 oncogenes are present concomitantly. Several observational studies and retrospective series have demonstrated that patients with DHL carry a poor prognosis and respond less and for a shorter duration to standard R-CHOP (rituximab, cyclophosphamide, vincristine, adriamycin, and prednisone)...
June 21, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/28699667/mantle-cell-lymphoma-2017-update-on-diagnosis-risk-stratification-and-clinical-management
#5
Julie M Vose
DISEASE OVERVIEW: Mantle cell lymphoma (MCL) is a non-Hodgkin lymphoma characterized by involvement of the lymph nodes, spleen, blood and bone marrow with a short remission duration to standard therapies and a median overall survival (OS) of 4-5 years. DIAGNOSIS: Diagnosis is based on lymph node, bone marrow, or tissue morphology of centrocytic lymphocytes, small cell type, or blastoid variant cells. A chromosomal translocation t (11:14) is the molecular hallmark of MCL, resulting in the overexpression of cyclin D1...
August 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28690315/targeting-nucleolin-for-better-survival-in-diffuse-large-b-cell-lymphoma
#6
N Jain, H Zhu, T Khashab, Q Ye, B George, R Mathur, R K Singh, Z Berkova, J F Wise, F K Braun, X Wang, K Patel, Z Y Xu-Monette, J Courty, K H Young, L Sehgal, F Samaniego
Anthracyclines have been a cornerstone in the cure of diffuse large B-cell lymphoma (DLBCL) and other hematological cancers. The ability of anthracyclines to eliminate DLBCL depends on the presence of topoisomerase-II-alpha (TopIIA), a DNA repair enzyme complex. We identified nucleolin as a novel binding partner of TopIIA. Abrogation of nucleolin sensitized DLBCL cells to TopIIA targeting agents (doxorubicin/etoposide). Silencing nucleolin and challenging DLBCL cells with doxorubicin enhanced the phosphorylation of H2AX (γH2AX-marker of DNA damage) and allowed DNA fragmentation...
July 10, 2017: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/28680723/gastric-adenocarcinoma-secondary-to-primary-gastric-diffuse-large-b-cell-lymphoma
#7
Riwa Sakr, Marcel Massoud, Georges Aftimos, Georges Chahine
Despite the decreasing incidence and mortality from gastric cancer, it remains a major health problem worldwide. Ninety percent of cases are adenocarcinomas. Here, we report a case of gastric adenocarcinoma developed after successful treatment of prior primary gastric diffuse large B-cell lymphoma (DLBCL). Our patient was an elderly man with primary gastric DLBCL in whom complete remission was achieved after R-CHOP (cyclophosphamide, adriamycin, vincristine, prednisolone plus rituximab) chemotherapy. Helicobacter pylori infection persisted despite adequate treatment leading to sustained chronic gastritis...
June 2017: Journal of Gastric Cancer
https://www.readbyqxmd.com/read/28668386/rituximab-dose-dense-chemotherapy-with-or-without-high-dose-chemotherapy-plus-autologous-stem-cell-transplantation-in-high-risk-diffuse-large-b-cell-lymphoma-dlcl04-final-results-of-a-multicentre-open-label-randomised-controlled-phase-3-study
#8
Annalisa Chiappella, Maurizio Martelli, Emanuele Angelucci, Ercole Brusamolino, Andrea Evangelista, Angelo Michele Carella, Caterina Stelitano, Giuseppe Rossi, Monica Balzarotti, Francesco Merli, Gianluca Gaidano, Vincenzo Pavone, Luigi Rigacci, Francesco Zaja, Alfonso D'Arco, Nicola Cascavilla, Eleonora Russo, Alessia Castellino, Manuel Gotti, Angela Giovanna Congiu, Maria Giuseppina Cabras, Alessandra Tucci, Claudio Agostinelli, Giovannino Ciccone, Stefano A Pileri, Umberto Vitolo
BACKGROUND: The prognosis of young patients with diffuse large B-cell lymphoma at high risk (age-adjusted International Prognostic Index [aa-IPI] score 2 or 3) treated with R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone) is poor. The aim of this study was to investigate the possible benefit of intensification with high-dose chemotherapy and autologous stem-cell transplantation as part of first-line treatment in these patients. METHODS: We did a multicentre, open-label, randomised, controlled, phase 3 trial with a 2 × 2 factorial design to compare, at two different R-CHOP dose levels, a full course of rituximab-dose-dense chemotherapy (no transplantation group) versus an abbreviated course of rituximab-dose-dense chemotherapy followed by consolidation with R-MAD (rituximab plus high-dose cytarabine plus mitoxantrone plus dexamethasone) and high-dose BEAM chemotherapy (carmustine, etoposide, cytarabine, and melphalan) plus autologous stem-cell transplantation (transplantation group) in young patients (18-65 years) with untreated high-risk diffuse large B-cell lymphoma (aa-IPI score 2-3)...
June 28, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28667319/infection-is-an-independent-predictor-of-death-in-diffuse-large-b-cell-lymphoma
#9
Claire Dendle, Michael Gilbertson, Tim Spelman, Rhonda L Stuart, Tony M Korman, Karin Thursky, Stephen Opat, Zoe McQuilten
To identify risk factors for infection in patients with diffuse large B cell lymphoma (DLBCL) undergoing rituximab, cyclophosphamide, vincristine, adriamycin and prednisolone (R-CHOP) treatment. All patients with DLBCL who received R-CHOP from 2004-2014 in a tertiary Australian hospital were identified and information collected from hospital admission data, laboratory results and medical record review. Infection was defined as hospitalisation with an ICD-10-AM diagnostic code for infection. Risk factors for infection and association between infection and survival were modelled using Cox proportional hazards regression...
June 30, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28665232/integrating-novel-drugs-to-chemoimmunotherapy-in-diffuse-large-b-cell-lymphoma
#10
Annalisa Chiappella, Elisa Santambrogio, Alessia Castellino, Maura Nicolosi, Umberto Vitolo
Diffuse Large B-cell Lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma (NHL), with an incidence in Europe of 3.8/100.000/year. A multi-drugs chemoimmunotherapy regimen, containing rituximab, cyclophosphamide, vincristine, doxorubicin and prednisone (R-CHOP) administrated every 21 days, is the standard therapy for DLBCL patients. The discovery of several biological features of DLBCL has encouraged the introduction of novel drugs in the treatment. Areas covered: In this article, the use of standard therapies will be reviewed and will be investigated adoption of novel drugs such as Bortezomib, Bruton's tyrosine kinase, IMiDs, Venetoclax, mTOR inhibitors and other biological agents...
June 30, 2017: Expert Review of Hematology
https://www.readbyqxmd.com/read/28648593/myc-rearranged-lymphomas-other-than-burkitt-comparison-between-r-chop-and-burkitt-type-immunochemotherapy
#11
Maria Joao Baptista, Gustavo Tapia, José-Ángel Hernández-Rivas, Alejandra Martínez-Trillos, José-Luis Mate, José-Tomás Navarro
BACKGROUND AND OBJECTIVE: MYC-rearranged (MYC-R) lymphomas other than Burkitt lymphoma (BL) are very aggressive, with poor prognosis when treated with standard regimens. We aimed to study the characteristics and outcome of a series of MYC-R lymphomas comparing the treatment results between R-CHOP based and a specific intensive regimen for BL (BURKIMAB). PATIENTS AND METHODS: Retrospective study of patients diagnosed with MYC-R. Translocations of MYC, BCL2 and BCL6 were evaluated by fluorescent in situ hybridization...
June 22, 2017: Medicina Clínica
https://www.readbyqxmd.com/read/28648087/cost-effectiveness-of-a-hepatitis-b-virus-screening-strategy-to-prevent-reactivation-in-patients-with-hematologic-neoplasms
#12
Javier Crespo, Rafael Esteban, Covadonga Torres, Itziar Oyagüez, Miguel Ángel Casado, María Buti
INTRODUCTION: The effectiveness of a screening strategy for the detection of a hepatitis B virus (HBV) infection followed by prophylaxis in order to prevent HBV reactivation was assessed in patients with hematologic neoplasms. MATERIAL AND METHODS: A decision tree was developed to compare the cost and effectiveness (prevented reactivations) over an 18 month period of a screening strategy prior to chemotherapy with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) with a non-screening approach...
June 26, 2017: Revista Española de Enfermedades Digestivas
https://www.readbyqxmd.com/read/28647936/18f-fdg-pet-ct-pulmonary-infiltrates-in-non-hodgkin-lymphoma-patients-treated-with-combined-immunochemotherapy-incidence-and-clinical-characteristics
#13
Yael C Cohen, Tamar Berger, Lora Eshel, Dorit Stern, Osnat Bairey, Pia Raanani, Ofer Shpilberg
BACKGROUND: Pulmonary infiltrates (PIs) detected in patients with non-Hodgkin lymphoma (NHL) may present a diagnostic challenge due to their wide differential diagnosis, including infection, pulmonary lymphoma and immunochemotherapy-associated pulmonary toxicity. OBJECTIVES: To characterize therapy-associated PIs by positron emission tomography/computed tomography (PET/CT) imaging. METHODS: We conducted a historical analysis of fluorodeoxyglucose-PET/CT (18F-FDG-PET/CT) PIs in NHL patients treated with combined immunochemotherapy including rituximab...
June 2017: Israel Medical Association Journal: IMAJ
https://www.readbyqxmd.com/read/28644138/comparative-analysis-of-primary-versus-relapse-refractory-dlbcl-identifies-shifts-in-mutation-spectrum
#14
Danielle M Greenawalt, Winnie S Liang, Sakina Saif, Justin Johnson, Petar Todorov, Austin Dulak, Daniel Enriquez, Rebecca Halperin, Ambar Ahmed, Vladislav Saveliev, John Carpten, David Craig, J Carl Barrett, Brian Dougherty, Michael Zinda, Stephen Fawell, Jonathan R Dry, Kate Byth
Current understanding of the mutation spectrum of relapsed/refractory (RR) tumors is limited. We performed whole exome sequencing (WES) on 47 diffuse large B cell lymphoma (DLBCL) tumors that persisted after R-CHOP treatment, 8 matched to primary biopsies. We compared genomic alterations from the RR cohort against two treatment-naïve DLBCL cohorts (n=112). While the overall number and types of mutations did not differ significantly, we identified frequency changes in DLBCL driver genes. The overall frequency of MYD88 mutant samples increased (12% to 19%), but we noted a decrease in p...
June 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28643323/favourable-outcomes-of-poor-prognosis-diffuse-large-b-cell-lymphoma-patients-treated-with-dose-dense-rituximab-high-dose-methotrexate-and-six-cycles-of-chop-14-compared-to-first-line-autologous-transplantation
#15
Tim Strüßmann, Kristina Fritsch, Axel Baumgarten, Thomas Fietz, Monika Engelhardt, Roland Mertelsmann, Gabriele Ihorst, Justus Duyster, Jürgen Finke, Reinhard Marks
The optimal therapeutic approach for young diffuse large B-cell lymphoma (DLBCL) patients with high-intermediate and high-risk age-adjusted international prognostic index (aaIPI) remains unknown. Hereby we report a 10-year single-centre study of 63 consecutively treated patients. To optimize outcome, two approaches were carried out: Cohort 1 patients received four cycles R-CHOP-21 (rituximab, cyclophosphamide, daunorubicin, vincristine, prednisolone over 21 days) followed by first-line high-dose chemotherapy with autologous stem-cell support (HDCT-ASCT), resulting in 2-year progression-free (PFS) and overall survival (OS) of 60·6% and 67·9%...
June 23, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/28640132/treatment-outcome-of-diffuse-large-b-cell-lymphoma-involving-the-head-and-neck-two-institutional-study-for-the-significance-of-radiotherapy-after-r-chop-chemotherapy
#16
MULTICENTER STUDY
Yoo-Kang Kwak, Byung-Ock Choi, Sung Hwan Kim, Joo Hwan Lee, Dae Gyu Kang, Jong Hoon Lee
This study was performed to analyze the treatment outcome for diffuse large B-cell lymphoma (DLBCL) involving the head and neck and to evaluate the role of radiotherapy in the rituximab era. Fifty-six patients diagnosed with DLBCL involving the head and neck were assessed. All patients were treated with 6 cycles of rituximab, cyclophosphamide, adriamycin, vincristine, and prednisolone (R-CHOP). After chemotherapy, radiation was delivered to the head and neck area in a median dose of 36 Gy. Radiation was delivered using 3-dimensional radiotherapy (n  =  25) or intensity-modulated radiotherapy (n  =  31)...
June 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28639256/response-and-survival-benefit-with-chemoimmunotherapy-in-epstein-barr-virus-positive-diffuse-large-b-cell-lymphoma
#17
Brady E Beltran, Pilar Quiñones, Domingo Morales, Jose M Malaga, Julio C Chavez, Eduardo M Sotomayor, Jorge J Castillo
Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) is a haematologic malignancy with poor prognosis when treated with chemotherapy. We evaluated response and survival benefits of chemoimmunotherapy in EBV-positive DLBCL patients. A total of 117 DLBCL patients were included in our retrospective analysis; 33 were EBV-positive (17 treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP] and 16 with CHOP), and 84 were EBV-negative (all treated with R-CHOP)...
June 22, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28629257/risk-stratification-of-diffuse-large-b-cell-lymphoma-with-interim-pet-ct-based-on-different-cutoff-deauville-scores
#18
Jihyun Kim, Yoo Sung Song, Jong Seok Lee, Won Woo Lee, Sang Eun Kim
We evaluated the usefulness of interim (18)F-FDG PET/CT for risk stratification using different cutoff values of the Deauville 5-point scale (5-DS) in DLBCL patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). One hundred and fifty patients underwent interim (I-) and end of treatment (EOT-) PET/CT scans. Applying the conventional 5-DS cutoff value of scores 4 to 5 at interim, there was no significant difference in progression free survival (PFS) between I-PET negative and I-PET positive patients...
June 20, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28622961/zoh%C3%A3-a-prospective-study-of-the-use-of-biosimilar-filgrastim-zarzio-in-clinical-practice-in-patients-treated-with-chemotherapy-for-lymphoid-malignancies
#19
Gandhi Laurent Damaj, Omar Benbrahim, Maya Hacini, Inna Voronina, Khaled Benabed, Ravaka-Fatoma Soumoudronga, Isabelle Gasnereau, Corinne Haioun, Philippe Solal-Céligny
BACKGROUND: The ZOHé study was a prospective, observational, multicenter study in France to assess use of biosimilar filgrastim Zarzio in routine clinical practice in patients undergoing neutropenia-inducing chemotherapy. PATIENTS AND METHODS: Patients ≥ 18 years undergoing chemotherapy for a malignant disease and with a first prescription for Zarzio were enrolled in 2 cohorts: solid tumor (1174 patients) or hematological malignancy (633 patients); the latter is reported here...
June 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/28602052/multicenter-retrospective-analysis-of-clinical-characteristics-treatment-patterns-and-outcomes-in-very-elderly-patients-with-diffuse-large-b-cell-lymphoma-the-korean-cancer-study-group-ly16-01
#20
Jung Hye Choi, Tae Min Kim, Hyo Jung Kim, Sung Ae Koh, Yeung-Chul Mun, Hye Jin Kang, Yun Hwa Jung, Hyeok Shim, So Young Chong, Der-Sheng Sun, Soonil Lee, Byeong Bae Park, Jung Hye Kwon, Seung-Hyun Nam, Jun Ho Yi, Young Jin Yuh, Jong-Youl Jin, Jae Joon Han, Seok-Hyun Kim
Purpose: The treatment strategy for elderly patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) has not been established because of poor treatment tolerability and lack of data. Materials and Methods: This multicenter retrospective study was conducted to investigate clinical characteristics, treatment patterns and outcomes of patients older than 80 years who were diagnosed with DLBCL at 19 institutions in Korea between 2005 and 2016. Results: A total of 194 patients were identified (median age, 83...
June 9, 2017: Cancer Research and Treatment: Official Journal of Korean Cancer Association
keyword
keyword
12044
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"